Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02460224 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 490
- Enrollment target
NCT02460224 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 490 participants.
The verdict
NCT02460224, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 490 participants
- Enrollment target
Study Summary
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation (phase 1) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion (phase 2) which characterized treatment of LAG525 in combination with PDR001 at the MTD or RP2D.
Interventions
- DRUG PDR001
- DRUG LAG525
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2015-06-17 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02460224
The ClinicalTrials.gov registry entry for NCT02460224 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PDR001 is the first listed.
NCT02460224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02460224 about?
NCT02460224 is a clinical study titled "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.". This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation (phase 1) to determine the maximum tol...
What is the current status of trial NCT02460224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 490 participants. The study started on 2015-06-17. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT02460224?
The interventions under investigation include: PDR001 (DRUG), LAG525 (DRUG).
Who is sponsoring clinical trial NCT02460224?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.